Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × rubitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 4 Ovarian Neoplasms 2 Lung Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Neoplasms 1 Melanoma 1 Liver Diseases 1 Leiomyosarcoma 1 Gliosarcoma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

pembrolizumab 256 Nivolumab 228 Ipilimumab 208 Cyclophosphamide 125 aldesleukin 123 Interleukin-2 92 Dacarbazine 68 trametinib 66 Temozolomide 66 fludarabine 64 Vemurafenib 63 dabrafenib 59 fludarabine phosphate 56 Radiosurgery 43 sargramostim 40 Biopsy 40 Bevacizumab 39 binimetinib 38 incomplete Freund's adjuvant 37 Paclitaxel 35 Cisplatin 34 Radiotherapy 33 encorafenib 31 atezolizumab 31 cobimetinib 30 Magnetic Resonance Spectroscopy 30 Carboplatin 29 Introns 28 Specimen Handling 27 CTLA-4 Antigen 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00005875 2013-12-04

Nitrocamptothecin in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡